Spark Therapeutics Inc
Most Recent
Most Analysts Have Given bluebird bio Positive Ratings in March
Wall Street analysts expect a potential upside of 19.21% for bluebird bio (BLUE) based on the company’s closing price on March 27.
A Look at Spark’s Potential Revenue Contribution to Roche Holdings
Wall Street analysts have projected Spark Therapeutics’ revenues to be $105.64 million, $169.22 million, and $263.76 million for fiscal 2019, fiscal 2020, and fiscal 2021, respectively.
Roche Holdings to Acquire Spark Therapeutics
On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).
How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
uniQure Stock Rose 35.7% Yesterday—Here’s Why
On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.
Editas Stock: Analysts’ Recommendations
In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”
What Spark Therapeutics’ Valuation Trend Indicates
Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
How Spark Therapeutics Is Positioned in 2018
Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.
BioMarin Pharmaceutical and Its Promising Research Pipeline
Stocks focused on gene therapy have garnered strong investor interest in 2018. In this series, we’ll analyze four of those companies.
Analysts Are Mostly Positive on Intellia Therapeutics This Month
On September 10, Intellia Therapeutics stock closed at $26.98, a ~0.95% fall from the previous day’s close of $27.24.
How Analysts Rate Editas Medicine and Peers in August
Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.
Why Achaogen Stock Fell Steeply Yesterday
Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options.
Why Axovant Sciences Stock Jumped ~160% on Wednesday
Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.
Recent Developments, Recommendations for JAZZ in May
In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application to the FDA for the label expansion of Xyrem.
Analysts’ Ratings for Sarepta Therapeutics and Peers in April
Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating.
How Analysts View Tetraphase Pharmaceuticals in April 2018
Of eight analysts tracking Tetraphase Pharmaceuticals, one analyst rated it as a “strong buy,” and six analysts gave it a “buy” rating.
Exploring Spark Therapeutics’ Cash Flows
Spark Therapeutics (ONCE) used $154.5 million in operating activities in 2017 compared to $80.4 million in 2016.
Exploring Spark Therapeutics’ Product Pipeline
Spark Therapeutics’ Luxturna was approved by the FDA in December 2017. It’s the first gene therapy approved for the treatment of a genetic disease.
Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.
Analysts Rate Voyager Therapeutics and Its Peers in April
Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.
Why Spark Therapeutics Stock Rose in the Week Ended March 29
On March 29, 2018, Spark Therapeutics was trading at $66.59, which represented a ~62% increase from its 52-week low of $41.06.
What Investors Should Know about Pfizer’s Recent Developments
The recent developments for Pfizer (PFE) include various product developments, pipeline developments, and commercial developments.